Result: Additional analyses carried out with rilpivirine resistance-associated mutations E138K/M184I or E138K/M184V showed that the combination of amino acid substitutions N348I and T369I had a dominant effect on the RNase H cleavage patterns observed with the PPT-containing 29RNA/28DNA template-primer complex (Figure 5).
Result: While preferential cleavage at the G*A site of the PPT/U3 junction was observed with mutants E138K/M184I and E138K/M184V and the WT HIV-1BH10 RT, the presence of N348I/T369I in any of those sequence contexts al
Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
Result: M184V and M184I were detected in seven and 18 samples respectively, the latter generally as a low-level variant (2-5%).
Discussion: The M184VI may also be linked with other DRMs and tends to wane over time due to overgrowth of more replication competent wild-type virus.
Discussion: The detection of some DRMs predominately at low levels is likely due to impaired viral fitness, which has been described for mutations such as M184VI and D30N.
Discussion: The most commonly detected NRTI DRMs, K219QENR and M184VI, occurred predominately as minor variants while the majority of patients with T215 revertants had the mutation in > 80% of the quasispecies.
High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
PMID: 33315694
2021
Journal of acquired immune deficiency syndromes (1999)
Abstract: BACKGROUND: The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance mutations from historical genotypic reports when switching from a tenofovir disoproxil fumarate-based or abacavir (ABC)-based regimen was investigated.
Abstract: CONCLUSIONS: The presence of the resistance mutations M184V/I did not jeopardize the efficacy of switching to E/C/F/TAF in virologically suppressed adults.
Abstract: METHODS: Virologically suppressed adults with HIV and documented M184V/I on historical genotypic records switched to E/C/F/TAF from a tenofovir disoproxil fumarate-based or ABC-based regimen.
Abstract: RESULTS: M184V alone was reported in 82.8% of 64 participants; 9.4% and 7.8%
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Abstract: M184I/V (emtricitabine RAM) was detected in one patient in each arm of AMBER.
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
PMID: 33200210
2021
The Journal of antimicrobial chemotherapy
Abstract: Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively.
Transmitted drug resistance to NRTIs and risk of virological failure in naive patients treated with integrase inhibitors.
Abstract: However, the presence of M184V/I independently predicted VF of raltegravir- but not dolutegravir-based therapy when compared with a fully-active backbone [adjusted hazard ratio (aHR) = 3.09, P = 0.035], particularly when associated with other non-thymidine analogue mutations (aHR = 27.62, P = 0.004).
Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan.
PMID: 32873061
2021
AIDS research and human retroviruses
Abstract: In ART-experienced patients, cohort II, 77.4% (82/106) of viruses contained at least one mutation against PIs, NRTIs, or NNRTIs, with the most common mutations of M184V/I (49.1%; 52/106), K65R (18.9%; 20/106), K103N (23.6%; 25/106), and G190S (22.6%; 24/106).
Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study.
Abstract: Major drug resistance mutations were detected in samples from 21 (14.6%) of 144 participants; the most frequent mutations were K103N and M184V/I.
[HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy in Taizhou city, 2016-2018].
PMID: 34814456
2021
Zhonghua liu xing bing xue za zhi
Abstract: The resistance mutations of NNRTIs and NRTIs were mainly K103 N (0.7%) and M184I/V (0.5%).
Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).
PMID: 34795836
2021
The Pan African medical journal
Abstract: The performance of the PANDAA assay in screening K65R, K103NS, M184VI, Y181C, and G190A mutations compared to the reference assay, Sanger sequencing was evaluated by Cohen s kappa coefficient on Stata version 14 (StataCorp LP, College Station, TX, USA).
Abstract: We assessed the performance of a rapid HIV-1 drug resistance assay, the Pan Degenerate Amplification and Adaptation (PANDAA) assay when screening for significant HIV-1 drug resistance mutations (DRMs) such as K65R, K103NS, M184VI, Y181C and G190A.
Introduction: Briefly, the PANDAA assay is an allelic discrimination test designed with different
HIV mutation literature information.
PMID: 
2021
Viruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT